Daratumumab for Familial Cerebral Cavernous Malformations: A Single-Arm Safety and Efficacy Study
Daratumumab for Familial Cerebral Cavernous Malformations: A Single-Arm Safety and Efficacy Study
Not yet recruiting · NCT07026604 · Registry updated 2025-06-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Daratumumab for Familial Cerebral Cavernous Malformations: A Single-Arm Safety and Efficacy Study | Cardiovascular Abnormalities, Cavernous Hemangioma of Brain, Cavernous Sinus Syndromes, Central Nervous System Vascular Malformations, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemangioma, Cavernous, Central Nervous System, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, brain disorder, cardiovascular disorder, cavernous hemangioma, central nervous system disorder, central nervous system malformation, hemangioma, hematologic disorder, hemorrhagic disease, neoplasm, nervous system disorder, vascular cancer, vascular disorder, vascular hemostatic disease, vascular malformation | Not yet recruiting | Early phase 1 | 2025-06-18 | NCT07026604 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Beijing Tiantan Hospital | 307 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beijing Tiantan Hospital | Beijing | China | 21 |